公开(公告)号：WO2023092091A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/080169

申请日：2022-11-18

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA

发明人： WEBBER, Beau ,  MORIARITY, Branden ,  BRIDGE, Jacob

IPC分类号： A61K35/17 ,  C12N5/07 ,  A61P35/00 ,  C07K14/725

摘要： Disclosed herein are methods of stimulating and expanding polyclonal gamma delta T cells (GDTCs) in vitro. More specifically, anti-gamma delta T cell receptor (GDTCR) antibody is used in combination with anti-CD28 antibody and one or more of IL-2, IL-7, and IL-15 to efficiently expand GDTCs in vitro.

公开(公告)号：WO2023092062A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/080131

申请日：2022-11-18

申请人： ANTHOS THERAPEUTICS, INC.

发明人： FREEDHOLM, Debra A. ,  BLOOMFIELD, Daniel M. ,  GLASSPOOL, Royston J. ,  FREEMAN, Jonathan E. ,  KHDER, Yasser

IPC分类号： A61K39/395 ,  A61K9/08 ,  A61P7/02 ,  C07K16/36

摘要： This disclosure relates to dosage regimens for anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for use in the treatment of thromboembolic disorders or related conditions. Also provided are pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are methods of treating patients having thrombocytopenias with anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof.

公开(公告)号：WO2023091968A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079987

申请日：2022-11-16

申请人： DISC MEDICINE, INC. ,  ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

发明人： MACDONALD, Brian ,  QUISEL, John ,  SAVAGE, Will ,  YANG, Hua ,  YU, Jonathan ,  WU, Min ,  BECONI, Maria ,  PEREZ, Jennifer, M. ,  MUELLER, Bernhard ,  POPP, Andreas

IPC分类号： A61P7/06 ,  C07K16/22 ,  C07K16/28 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

摘要： Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

公开(公告)号：WO2023091951A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079966

申请日：2022-11-16

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： LO, Roger S. ,  YANG, Zhentao

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/18

摘要： Described are methods for enhancing cancer immune surveillance and the efficacy of the treatment of melanoma or non-melanoma cancers such as pancreatic or colorectal cancers, particularly by controlling cancer cell-surface PD-L1/L2 and the E3 ligase ITCH. Also described are methods of inhibiting an adaptive immune resistance response to anti-immune checkpoint protein therapy in a subject. As described herein, the efficacy of MAPK inhibitor therapy is increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2. As further demonstrated herein, the efficacy of anti-PD-1/L1 therapy is also increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2.

公开(公告)号：WO2023091878A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079687

申请日：2022-11-11

申请人： DANISCO US INC.

发明人： MA, Zhen ,  FRISCH, Ryan ,  PAUL, Brian ,  DOIG, Steven

IPC分类号： C12N15/03 ,  C07K14/32

摘要： Certain embodiments of the disclosure are related to recombinant Bacillus strains comprising enhanced protein productivity phenotypes, compositions and methods for constructing such recombinant Bacillus cells, and the like. The recombinant Bacillus strains described herein are particularly useful for the enhanced production of proteins of interest when grown/cultivated/fermented under suitable conditions.

公开(公告)号：WO2023091865A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079442

申请日：2022-11-08

申请人： CELLDEX THERAPEUTICS, INC. ,  BIOSION, INC.

发明人： KELLER, Tibor ,  GOLDSTEIN, Joel ,  MURPHY, Michael ,  O'NEILL, Thomas ,  VITALE, Laura, A. ,  CHEN, Mingjiu

IPC分类号： C07K16/28 ,  A61K39/00

摘要： Provided herein are novel anti-ILT4 and anti-PD- 1 bispecific constructs, as well as corresponding compositions. Methods of inducing or enhancing an immune response, and methods of treating cancer, by administering the constructs or compositions also are described.

公开(公告)号：WO2023091503A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/050129

申请日：2022-11-16

申请人： SURGE THERAPEUTICS, INC.

发明人： GOLDBERG, Michael Solomon

IPC分类号： A61K38/19 ,  A61K47/36 ,  A61K47/42 ,  A61P35/00 ,  C07K14/705 ,  C12N15/63

摘要： Provided are compositions useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a provided composition comprises a biodegradable scaffold or biomaterial comprising one or more nucleic acid agents that may act to themselves promote or inhibit an immunomodulatory pathway, and/or may encode a peptide which may promote or inhibit an immunomodulatory pathway. Also provided are methods of making provided compositions as well as kits containing materials to provide the same.

公开(公告)号：WO2023090771A1

公开(公告)日：2023-05-25

申请号：PCT/KR2022/017801

申请日：2022-11-11

申请人： 대한민국(농림축산식품부 농림축산검역본부장)

发明人： 이민자 ,  김현미 ,  신세희 ,  김수미 ,  박종현

IPC分类号： C12N15/63 ,  C12N7/00 ,  C07K14/005 ,  G01N33/569 ,  A61K39/135 ,  A61P31/14

摘要： 본 발명은 재조합 구제역 바이러스, 상기 바이러스로부터 분리·정제된 항원을 포함하는 구제역 백신 조성물에 관한 것으로, 백신 접종 초기, 강력한 세포성 면역반응의 유도를 통해 체액성 면역반응을 동시에 유도하는 한편, 모체이행항체 (MDA, maternally-derived antibody) 존재 시 B 세포 수용체의 자극을 통해 모치이행항체의 간섭 극복 및 능동면역이 가능하게 한 백신 조성물과 상기 조성물을 이용한 구제역의 예방 또는 치료 방법을 제공할 수 있다.

公开(公告)号：WO2023089594A1

公开(公告)日：2023-05-25

申请号：PCT/IB2022/061286

申请日：2022-11-22

申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED

发明人： YADAV, Arunkumar ,  PANDYA, Kunal ,  TAILOR, Bhavna ,  PATEL, Brijesh ,  JOSHI, Jigar ,  PATEL, Vipulkumar ,  PRASAD, Mohan

IPC分类号： C07K14/575 ,  A61K38/00 ,  C07C233/47 ,  C07K1/04 ,  C07K14/00 ,  C07K14/605

摘要： The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of tirzepatide.

公开(公告)号：WO2023089556A1

公开(公告)日：2023-05-25

申请号：PCT/IB2022/061148

申请日：2022-11-18

申请人： PFIZER INC.

发明人： AGOSTINO, Michael John ,  ARAT, Seda ,  CAUBEL, Patrick Michel ,  GOSINK, Mark Matthew ,  KHAN, Kanwar Nasir Mahmood ,  KOZA-TAYLOR, Petra Helen ,  MARTIN, Matthew Thomas

IPC分类号： A61K39/12 ,  A61P31/14 ,  C07K16/08 ,  A61K39/00

摘要： The present disclosure provides methods of reducing risk of antigen mimicry in immunogenic medicaments. The present disclosure also provides immunogenic compositions comprising antigenic polypeptide constructs having a reduced risk of antigen mimicry.